Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan

No abstract is available for this paper.

• Publication year

  2015

• Venue

  International Journal of Clinical Oncology

• Publication date

  2015-02-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10147-015-0786-7PMID 25681876
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic factors for chemotherapy induced nausea and vomiting.

  2014cited by this paper
• Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.

  2014cited by this paper
• The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).

  2012cited by this paper
• The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).

  2012cited by this paper
• Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

  2011cited by this paper
• Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.

  2011cited by this paper
• Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy

  2011cited by this paper
• Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study

  2011cited by this paper
• Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists

  2011cited by this paper
• Insight in the prediction of chemotherapy-induced nausea

  2010cited by this paper
• Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy

  2010cited by this paper
• Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

  2010cited by this paper
• Patient- and Treatment-Related Risk Factors for Nausea and Emesis during Concurrent Chemoradiotherapy

  2010cited by this paper
• Clinical Predictors of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients Receiving Adjuvant Doxorubicin and Cyclophosphamide

  2009cited by this paper
• NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

  2009cited by this paper
• Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials

  2005cited by this paper
• Patient expectation is a strong predictor of severe nausea after chemotherapy

  2004cited by this paper
• Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics

  2004cited by this paper
• Patient expectations as predictor of chemotherapy-induced nausea

  2000cited by this paper
• Proceedings of the American Society of Clinical Oncology

  1982cited by this paper

• Evaluating the potential to predict chemotherapy-induced nausea and vomiting in carboplatin-containing treatment based on symptoms induced by prior cisplatin-containing treatment

  2026cites this paper
• Age-Stratified Risk of Carboplatin-Induced Nausea and Vomiting in Lung Cancer Patients

  2025cites this paper
• Evaluation of nausea induced by trifluridine/tipiracil in metastatic colorectal cancer treatment.

  2025cites this paper
• Olanzapine Versus NK1 Receptor Antagonist for Prevention of Carboplatin-Induced (AUC ≥4) Emesis: A Phase III, Double-Blind, Placebo-Controlled Randomized Trial From India

  2025cites this paper
• Optimizing Antiemetic Support in Anthracycline-Based Chemotherapy for Early Breast Cancer: Protocol for a Prospective Observational Study of Four-Drug Antiemetic Therapy Including Fosnetupitant and Olanzapine

  2025cites this paper
• Development and validation of predictive model for emesis in cervical cancer patients receiving concurrent chemoradiotherapy based on multi-institutional retrospective study

  2025cites this paper
• Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials

  2025cites this paper
• Total neoadjuvant therapy in early-onset versus average-onset locally advanced rectal cancer: patient characteristics and tolerance of therapy

  2025cites this paper
• Evaluation of the Efficacy of 2.5 mg Olanzapine to Prevent Anthracycline and Cyclophosphamide Combination Therapy-induced Nausea and Vomiting

  2025cites this paper
• Cost-effectiveness analysis of fosnetupitant in patients receiving cisplatin in Japan: analysis based on real-world data

  2025influential citation
• Evaluation of Antiemetic Consistency in Chemotherapy-Induced Nausea and Vomiting Among NHL Patients in Sana’a, Yemen

  2024cites this paper
• A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II)

  2024cites this paper
• Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical onco

  2024cites this paper
• Dexamethasone-sparing strategies in anthracycline and cyclophosphamide-based chemotherapy with a focus on 5-HT3 receptor antagonists: a network meta-analysis

  2024cites this paper
• Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial

  2024cites this paper
• A nurse-led multidomain intervention to improve the management of chemotherapy-induced nausea and vomiting in patients with head and neck cancers: A randomized controlled trial.

  2024cites this paper
• Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023

  2024cites this paper
• Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials

  2024cites this paper
• Comparing the Efficacy of Fosnetupitant, an NK1 Receptor Antagonist in CDDP-Based Regimens, With that of Fosaprepitant and Aprepitant: A Retrospective Observational Study.

  2024cites this paper
• Investigating the efficacy and safety of olanzapine prophylaxis for opioid-induced nausea and vomiting (JORTC-PAL20): a study protocol for an open-label, single-arm exploratory study

  2024cites this paper
• Asenapine versus olanzapine for the treatment of nausea and vomiting in patients with cancer: A retrospective study

  2024cites this paper
• Effect of Mirtazapine for the Prevention of Nausea and Vomiting in Patients With Thoracic Cancer Receiving Platinum-based Chemotherapy

  2023cites this paper
• Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy

  2023influential citation
• Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study

  2023cites this paper
• Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase

  2023cites this paper
• Influence of menopause on chemotherapy‐induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study

  2023cites this paper
• Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)—a systematic review and individual patient data meta-analysis

  2023cites this paper
• Olanzapine treatment effectively relieves breakthrough chemotherapy-induced nausea and vomiting: a real-world experience

  2023cites this paper
• Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy

  2023cites this paper
• Multi-institutional survey of antiemetic therapy in lung cancer patients treated with carboplatin in Hokushin region

  2023cites this paper
• Conditioned nausea induced by cisplatin and emetine identified by a taste reactivity test in rats.

  2023cites this paper
• Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy

  2023cites this paper
• Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy

  2023cites this paper
• Fosnetupitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Short Review and Clinical Perspective

  2023influential citation
• One-Day Versus Three-Day Dexamethasone with NK1RA for Patients Receiving Carboplatin and Moderate Emetogenic Chemotherapy: A Network Meta-analysis

  2022cites this paper
• The Effectiveness of an Oral Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) in Patients With Multiple Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Observational Indian Study

  2022cites this paper
• The efficacy of single dose palonosetron in highly emetogenic chemotherapy protocols compared to oral aprepitant and ondansetron

  2022cites this paper
• A retrospective study on chemotherapy-induced nausea and vomiting in highly/moderately emetogenic chemotherapy: incidence and prescribing practice

  2022cites this paper
• Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation

  2022cites this paper
• Influence of Dose Reduction of Prophylactic Dexamethasone on Chemotherapy-induced Nausea and Anorexia in Patients Under 55 Years Old Treated With Anthracycline-containing Regimens

  2022cites this paper
• Factors affecting the implementation of guideline-based prophylactic antiemetic therapy for chemotherapy-induced nausea and vomiting in Japan: a protocol for a hospital-based qualitative study

  2022cites this paper
• The longitudinal effects of chronotype on chemotherapy-induced nausea and vomiting in patients with breast cancer receiving neoadjuvant chemotherapy.

  2022cites this paper
• Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis

  2021cites this paper
• Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis

  2021influential citation
• Moderating effect of sense of coherence on the relationship between symptom distress and health-related quality of life in patients receiving cancer chemotherapy

  2021cites this paper
• Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China

  2021cites this paper
• Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score–matched analysis

  2021cites this paper
• Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy: a prospective trial.

  2021cites this paper
• Platinum-induced nausea and vomiting in patients treated for head and neck cancer.

  2021cites this paper
• Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment

  2021cites this paper
• Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE

  2021cites this paper
• Establishment of an antiemetic protocol for chemotherapy-induced nausea and vomiting evaluated using the Multinational Association of Supportive Care in Cancer Antiemesis Tool in colorectal cancer

  2021cites this paper
• Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk

  2021cites this paper
• Comparison of Chemotherapy-induced Nausea and Vomiting Between Gemcitabine Plus Nab-paclitaxel Combination Chemotherapy and Gemcitabine Monotherapy in Patients With Advanced Pancreatic Cancer

  2021cites this paper
• Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: a prospective cohort study (YCOG1301)

  2020cites this paper
• 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study

  2020cites this paper
• Patient-related Risk Factors for Nausea and Vomiting With Standard Antiemetics in Patients With Cancer Receiving Carboplatin: A Retrospective Study.

  2020cites this paper
• Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis

  2020cites this paper
• A double‐blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide

  2020cites this paper
• Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective

  2020cites this paper
• Patient-Related Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review

  2020influential citation
• Outcomes of Clinical Pharmacy Research Aimed at Avoiding or Reducing Cancer Chemotherapy-induced Adverse Reaction

  2020cites this paper
• 5HT3RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy‐induced nausea and vomiting in colorectal cancer

  2020cites this paper
• Nausea and vomiting during post-transplantation cyclophosphamide administration

  2020cites this paper
• Relationship between PONV and S-1 Adjuvant Chemotherapy-associated Nausea

  2019cites this paper
• Effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline-induced nausea and vomiting.

  2019cites this paper
• Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting

  2019cites this paper
• Prophylactic Antiemetics for Haematological Malignancies: Prospective Nationwide Survey Subset Analysis in Japan

  2019cites this paper
• Multicenter, placebo‐controlled, double‐blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy

  2019cites this paper
• Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study

  2019cites this paper
• A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin‐Based Chemotherapy‐Induced Nausea and Vomiting in Japan

  2019influential citation
• Dexamethasone-sparing regimen is an effective and safe alternative in overall antiemetic protection

  2019cites this paper
• Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin

  2019cites this paper
• Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study

  2019cites this paper
• Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study

  2018cites this paper
• Patient-related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-based Chemotherapy: A Retrospective Observational Study.

  2018cites this paper
• A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy

  2018influential citation
• Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.

  2018cites this paper
• Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy.

  2018cites this paper
• [Effects of Serum Sodium Concentrations on Nausea and Vomiting after Moderately Emetogenic Chemotherapy].

  2018cites this paper
• Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial

  2018cites this paper
• Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis

  2018cites this paper
• Evaluation of Combination Antiemetic Therapy on CINV in Patients With Gynecologic Cancer Receiving TC Chemotherapy

  2018cites this paper
• A dose-finding randomized Phase II study of oral netupitant in combination with palonosetron .75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy

  2018cites this paper
• Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)

  2018cites this paper
• Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study

  2018cites this paper
• NCCN Guidelines Insights: Antiemesis, Version 2.2017.

  2017cites this paper
• Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.

  2017cites this paper
• Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea

  2017cites this paper
• Efficacy of aprepitant for CHOP chemotherapy-induced nausea, vomiting, and anorexia.

  2017cites this paper
• Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan

  2017cites this paper
• Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy.

  2017cites this paper
• Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk

  2017cites this paper
• Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior to Palonosetron in Gastrointestinal Cancer Patients Who Received Moderately Emetogenic Chemotherapy

  2017cites this paper
• The efficacy of the Kampo medicine rikkunshito for chemotherapy-induced anorexia (RICH trial): study protocol for a randomized controlled trial

  2017cites this paper
• Patient perceptions of symptoms and concerns during cancer chemotherapy: ‘affects my family’ is the most important

  2017cites this paper
• Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan

  2017cites this paper
• Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy

  2017cites this paper
• Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline‐based Chemotherapy

  2017cites this paper
• A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting

  2017cites this paper